Revenue grew 66% in Q4 and 59% for FY 2026, driven by commercial expansion, clinical evidence, and product innovation. Gross margin expanded over 10 points, and FY 2027 guidance targets 44% revenue growth with continued margin improvement and operating leverage.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.